コレリアック病は,

Same author

High levels of genetic diversity in island populations of the island endemic Suzukia luchuensis (Labiatae).

Heredity·2003

Same author

Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease.

Tissue antigens·2003

Same author

Genetic dissection between silent and clinically diagnosed symptomatic forms of coeliac disease in multiplex families.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2003

Same author

Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study.

Alimentary pharmacology & therapeutics·2003

Same author

Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors.

International journal of radiation biology·2003

Same author

Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues.

Gut·2003

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

コレリアック病は,

関連する概念動画

High levels of genetic diversity in island populations of the island endemic Suzukia luchuensis (Labiatae).

Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease.

Genetic dissection between silent and clinically diagnosed symptomatic forms of coeliac disease in multiplex families.

Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study.

Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors.

Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

コレリアック病は,

関連する概念動画

関連記事

High levels of genetic diversity in island populations of the island endemic Suzukia luchuensis (Labiatae).

Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease.

Genetic dissection between silent and clinically diagnosed symptomatic forms of coeliac disease in multiplex families.

Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study.

Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors.

Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.